A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-31

Study Completion Date

2016-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study was designed to evaluate how CORT125134 is taken up, broken down and removed from the body when given as an oral capsule to healthy subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants

NCT03877952

Healthy

COMPLETED PHASE1

Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants

NCT04990310

Healthy

COMPLETED PHASE1

Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants

NCT03878264

Healthy

COMPLETED PHASE1

A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects

NCT06094712

Healthy

COMPLETED PHASE1

A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects

NCT06094790

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study was conducted to determine the recovery of \[14C\]-CORT125134 after the administration of a single oral dose of \[14C\]-CORT125134, to determine the routes and rate of elimination of \[14C\]-CORT125134 and associated radioactivity from the body, and to measure concentrations of radioactivity in the blood. Additional objectives of the study were to determine the chemical structure of each significant metabolite in plasma, urine and feces. Safety and tolerability were assessed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

[14C]-CORT125134

Two capsules each containing 125 milligrams (mg) \[14C\]-CORT125134 administered to each participant on 1 occasion

Group Type EXPERIMENTAL

[14C]-CORT125134

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[14C]-CORT125134

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy males or healthy females of non-childbearing potential (surgically sterilized or postmenopausal \[defined as a woman of with at least a 12 month history of amenorrhea with a follicle-stimulating hormone (FSH) \>40 international units per liter (IU/L) in the absence of a reversible medical iatrogenic cause\])
* Age 30 to 65 years of age
* A history of regular bowel movements (averaging ≥1 and ≤3 stools per day)
* Must be willing and able to communicate and participate in the whole study
* Must provide written informed consent
* Male participants must agree to use an adequate method of contraception
* Participants are willing to abide by the study restrictions

Exclusion Criteria

* Participation in a clinical research study within the previous 3 months
* Participants who have previously been enrolled in this study or participants who have previously been treated with CORT125134
* History of any drug or alcohol abuse in the past 2 years
* Regular alcohol consumption in males \>21 units per week and females \>14 units per week (1 unit = ½ pint beer, 25 milliliter (mL) of 40% spirit or a 125 mL glass of wine)
* Current smokers and those who have smoked within the last 12 months; this includes cigarettes, e-cigarettes and nicotine replacement products. A breath carbon monoxide reading of greater than 10 parts per million (ppm)
* Females of childbearing potential (female participants must have a negative urine pregnancy test)
* Male Participants with pregnant partners
* Radiation exposure exceeding 5 millisievert (mSv) in the last 12 months or 10 mSv in the last 5 years. The measurement includes exposure from the present study, and diagnostic x rays and other medical exposures, but excludes background radiation. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999.
* Positive drugs of abuse test result
* Participants who are taking, or have taken, any prescribed or over-the-counter drug (other than 4 grams per day paracetamol) or herbal remedies in the 14 days before study drug administration. Hormone replacement therapy is not permitted

Minimum Eligible Age

30 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes